背景:在过去的20年里,在对淋巴管平滑肌瘤病(LAM)的临床和发病机制的认识方面取得了很大进展,导致指南的出版和有效治疗的批准。
目的:我们的研究目的是描述ERS和美国胸科学会/日本呼吸学会指南的发表以及西罗莫司的引入后,这种罕见疾病的管理和自然史发生了怎样的变化。
方法:我们检查了2001年至2017年间在我们中心随访的162名LAM患者,报告了临床特征和诊断方法。接受长期治疗的患者对西罗莫司的反应和死亡风险,考虑到器官移植作为事件的竞争原因,根据累积发生率进行估计,进行了评估。2011年之前接受观察的患者与2011年之后的西罗莫司疗效MILES试验发表年份的累积发生率差异,也被估计了。
结果:61例患者有组织学诊断(从2010年起有22例)。101例患者根据指南标准接受放射学诊断。在接受西罗莫司治疗超过12个月的患者中,肺功能检查在3年的治疗期内保持稳定。在整个人群中,10年后的累计死亡率为25.5%。自2011年(MILES试验发表后)进入研究的患者5年后的累积死亡率显著低于之前进入研究的患者。
结论:我们提供的数据支持西罗莫司治疗在患有功能障碍和其他疾病表现的大型队列患者中的长期疗效。我们的结果还表明,西罗莫司的出现和国际指南的发表改变了疾病的自然史,从而降低了死亡率并减少了对侵入性诊断技术的需求。
BACKGROUND: Over the last 2 decades, great progress has been made in the understanding of the clinical aspects and pathogenesis of lymphangioleiomyomatosis (LAM), leading to publication of guidelines and approval of an effective therapy.
OBJECTIVE: Aim of our study was to describe how the management and the natural history of this rare disease have changed after the publication of the ERS and American Thoracic Society/Japanese Respiratory Society guidelines and the introduction of sirolimus.
METHODS: We examined 162 LAM patients followed at our center between 2001 and 2017, reporting clinical characteristics and diagnostic approach. Response to sirolimus in patients undergoing long-term treatment and mortality risk, estimated in terms of cumulative incidence taking into account organ transplantation as a competing cause of the event, were evaluated. The difference in the cumulative incidence between the patients admitted to the observation before 2011 and after 2011, year of the publication of the MILES trial for the efficacy of sirolimus, has also been estimated.
RESULTS: Sixty-one patients had a histological diagnosis (22 from 2010 onward). 101 patients received a radiological diagnosis according to the guidelines criteria. Pulmonary function tests remained stable over a 3-year treatment period in patients who received sirolimus for over 12 months. The cumulative incidence of mortality after 10 years in the whole population was 25.5%. The cumulative incidence of mortality after 5 years was significantly lower in patients who entered the study since 2011 (after publication of the MILES trial) than in patients who entered the study before.
CONCLUSIONS: We provide the data supporting the long-term efficacy of sirolimus therapy in a large cohort of patients with functional impairment and other manifestations of the disease. Our results also suggest that the advent of sirolimus and the publication of international guidelines changed the natural history of the disease lowering the mortality and reducing the need of invasive diagnostic techniques.